Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV,... Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase a,b a a a John M. Murray , Sean Emery , Anthony D. Kelleher , Matthew Law , c c c Joshua Chen , Daria J. Hazuda , Bach-Yen T. Nguyen , c a Hedy Teppler and David A. Cooper Objective: Raltegravir (MK-0518) belongs to the new class of HIV integrase inhibitors. To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs. Methods: Patients in this phase II study (P004) were antiretroviral treatment naive. Part 1 of this study compared monotherapy with raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily) with placebo over 10 days. In part 2, patients were enrolled for 48 weeks of combination therapy, with randomization to one of the four dosages of raltegravir or to efavirenz, in addition to tenofovir and lamivudine. Mathematical models were used to investigate processes underlying viral dynamics. Results: From day 15 through to day 57, individuals in the raltegravir arm were significantly more likely to have HIV RNA < 50 copies/ml (P 0.047). Plasma viral http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Wolters Kluwer Health

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

AIDS , Volume 21 (17) – Nov 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/antiretroviral-therapy-with-the-integrase-inhibitor-raltegravir-alters-A0262JFr53

References (21)

ISSN
0269-9370
eISSN
1473-5571
DOI
10.1097/QAD.0b013e3282f12377
pmid
18090280
Publisher site
See Article on Publisher Site

Abstract

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase a,b a a a John M. Murray , Sean Emery , Anthony D. Kelleher , Matthew Law , c c c Joshua Chen , Daria J. Hazuda , Bach-Yen T. Nguyen , c a Hedy Teppler and David A. Cooper Objective: Raltegravir (MK-0518) belongs to the new class of HIV integrase inhibitors. To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs. Methods: Patients in this phase II study (P004) were antiretroviral treatment naive. Part 1 of this study compared monotherapy with raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily) with placebo over 10 days. In part 2, patients were enrolled for 48 weeks of combination therapy, with randomization to one of the four dosages of raltegravir or to efavirenz, in addition to tenofovir and lamivudine. Mathematical models were used to investigate processes underlying viral dynamics. Results: From day 15 through to day 57, individuals in the raltegravir arm were significantly more likely to have HIV RNA < 50 copies/ml (P 0.047). Plasma viral

Journal

AIDSWolters Kluwer Health

Published: Nov 1, 2007

There are no references for this article.